Lasolvan® (ambroxol)

23.09.2014 Updated 22.10.2019 5391 views

By MoH of Ukraine Order No. 652 of 18.09.14, the package insert (hereinafter – the insert) of the original (reference) medicinal product containing ambroxol, namely Lazolvan®, tablets, was approved with amendments and additions to the following sections of the insert: “Contraindications”, “Adverse Reactions”, “Overdose”, “Use during Pregnancy or Breastfeeding”, “Appropriate Safety Precautions for Use”.